Cadent Therapeutics, Inc.

Infinity Pharmaceuticals, Inc.

Eisai R&d Management Co., Ltd.

Infinity Discovery, Inc.

Third Harmonic Bio, Inc.

Novartis Ag

Gregg F Keaney

Marta Nevalainen

Alfredo C Castro

Stephane Peluso

Thomas T Tibbitts

Daniel A Snyder

Adilah Bahadoor

Martin R Jefson

Janus Schreiber Larsen

Thomas Amos Jacobsen

Robert A Volkmann

John JianShi Wang

David R Anderson

Edward Holson

Michael J Grogan

Tao Liu

Guo Zhu Zheng

Brian T Hopkins

Yoshihiko Kotake

Lawrence Blas Perez

Kazunobu Kira

Parcharee Tivitmahaisoon

Sudeep Prajapati

Norio Murai

Karin Sandager Nielsen

Baudouin Gerard

Nii O Koney

Xiang Liu

Timothy Piser

Lawrence K Chan

Satoshi Nagao

Charles W Johannes

Kristopher M Depew

Masayuki Miyano

Vesa Nevalainen

David A Mann

Kenzo Arai

Kelly Foster

Dipak Vasantrao Amrutkar

Steven C Leiser

Sam Malekiani

Regina Mikie Kanada Sonobe

Nicholas C Gearhart

Brian C Austad

Atsushi Endo

Somarajannair Janardanannair

Peter G Smith

Silvia Buonamici

Lihua Yu

Ermira Pazolli

Charles William Johannes

Eunice Sun Park

Kian Huat Lim

Priscilla L White

Michael P Thomas

Betty Chan

Sheldon L Wallerstein

Jitendra D Belani

John Adams Lowe, Iii

John Michael McCall

Ming-Hong Hao

Dominic J Reynolds

Birgitte Langer Eriksen

Andrew Cook

Jonathan James Loughrey

Arani Chanda

Charlotte Hougaard

Jason T Lowe

Dorte Strøbæk

Magnus Gustafsson

James Palacino

Shelby Ellery

Jaclyn Raeburn

Lisa A Marcaurelle

Jun Xu

Tuoping Luo

Morgan Welzel O'shea

Wenfeng Xue

Yuxiang Song

Jessica Klein

Leonard Walter Rozamus, Jr

Nadia Lybøl Von Schoubye

Elizabeth Kwong

Regina Mikie Kanada Sonabe

Regina Kanada Sonobe

Sundeep Prajapati

Edward B Holson

Provided herein are crystalline and amorphous forms of a compound having structural formula (1). Also provided are pharmaceutical compositions comprising the crystalline and amorphous forms, methods for their manufacture, and uses thereof for treating a variety of diseases, disorders or conditions, associated with potassium channels.

Crystalline forms of potassium channel modulators

The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Certain pladienolide compounds and methods of use

The present disclosure relates generally to various forms and compositions of N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide useful as a selective inhibitor of c-kit kinase and uses of the same in the treatment of c-kit kinase associated diseases.

Crystalline forms of a selective c-kit kinase inhibitor

The present disclosure relates generally to pharmaceutical compositions of N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide useful as a selective inhibitor of c-kit kinase and uses of the same in the treatment of c-kit kinase associated diseases.

Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same

Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.

Heteroaromatic NMDA receptor modulators and uses thereof

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels. 

Potassium channel modulators

The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful. 

Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof

Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.

Provided herein are compounds of the formula: or pharmaceutically acceptable salts thereof, and compositions comprising such compounds for use in the treatment of diseases or conditions responsive to modulation of the small conductance calcium-activated potassium channel (SK channel).

The invention relates to the preparation of amino-cyclopamines by the enzymatic transamination of a corresponding keto-cyclopamines in the presence of a cofactor and an amino donor.

Enzymatic transamination of cyclopamine analogs

The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.

Pladienolide pyridine compounds and methods of use

Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables R, Rand Rare defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Tetrazolones as inhibitors of fatty acid synthase

Growing community of inventors

Lexington, MA, United States of America

Gregg F Keaney